Geneva, Switzerland and Boston, MA -December 7, 2017 - ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that company management will participate in the BMO Prescriptions for Success Healthcare Conference on December 14th, 2017, in New York City.
ObsEva's presentation will take place on Thursday, December 14th, 2017, at 3.00 p.m. Eastern Time (ET). A webcast will be available in the "Investors" section of ObsEva's website www.ObsEva.com.
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving ART outcomes. ObsEva is listed on The NASDAQ Global Select Market and is trading under the ticker symbol "OBSV". For more information, please visit www.ObsEva.com.
Media Contact:Liz BryanSpectrum Sciencelbryan@spectrumscience.com+1 202-955-6222 x2526
CEO Office contactShauna DillonShauna.email@example.com+41 22 552 1550
Investor ContactMario CorsoSenior Director, Investor Relationsmario.firstname.lastname@example.org+1 781-366-5726
Press releaseThis announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.Source: ObsEva SA via Globenewswire --- End of Message --- ObsEva SAChemin des Aulx; 12 Plan-les-Ouates Switzerland
Les dernières news
News les plus lues